| Schedule of potentially dilutive outstanding instruments which were not included in the computation of diluted EPS |
| | | | | | | | As of June 30, | | | | 2025 | | 2024 | | Common stock purchase warrants | | 1,467,581 | | 1,150,834 | | Stock options | | 300,467 | | 56,699 | | Convertible debt | | — | | 100,947 | | Total | | 1,768,048 | | 1,308,480 | |
|
| Schedule of impact of the correction on the Company's condensed consolidated balance sheet |
The accompanying results of operations for the three and six-month periods ended June 30, 2025, appropriately reflect the accrual, timing and recognition of costs related to product development. | | | | | | | | | | | | | Impact of correction of error | | | | As previously reported | | | Adjustments | | | As restated | As of March 31, 2025: (unaudited) | | | | | | | | | | Accrued expenses | | $ | 3,404,332 | | $ | (285,495) | | $ | 3,118,837 | Total liabilities | | $ | 4,133,682 | | $ | (285,495) | | $ | 3,848,187 | Total liabilities and shareholder's equity | | $ | 7,746,120 | | $ | - | | $ | 7,746,120 | For the three months ended March 31, 2025: (unaudited) | | | | | | | | | | Research and development expenses | | $ | 2,227,175 | | $ | (285,495) | | $ | 1,941,680 | Total operating expenses | | $ | 3,312,003 | | $ | (285,495) | | $ | 3,026,508 | Loss from operations | | $ | (3,312,003) | | $ | 285,495 | | $ | (3,026,508) | Net loss applicable to common stockholders | | $ | (3,236,763) | | $ | 285,495 | | $ | (2,951,268) | Basic and diluted net loss per share | | $ | (1.06) | | $ | 0.09 | | $ | (0.97) |
|